OncoPharm

Recent FDA & #oncopharm updates are discussed, including irinotecan in sweat, fostamatinib's FDA-approval for ITP. Then, immunotherapy updates from AACR are reviewed (6:00). Finally (34:00 , osimertinib's updated approval for frontline use in mEGFR NSCLC.

You've heard of NSABP, but have you heard of adjuvant melphalan, 5-FU, & concurrent tamoxifen? Sometimes asking the right question yields answers we don't yet understand.

The Foundations in Oncology Pharmacy continues with vincristine. Its origin, unique toxicity profile, and clinical use is discussed. Periwinkle!

Highlights from last week's HOPA annual conference are discussed, followed by (13:09) a lightning-style run through of #oncopharm updates over the last 2 weeks.

Previewing HOPA18 and its highly anticipated sessions, networking opportunities, and virtual attendance.

PVB's (cisplatin, vinblastine, bleomycin) impressive cure rate for testicular cancer is 1977 is discussed. Then the evolution of the BEP & EP regimen is summarized.

Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.

Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.

Apalutamide's FDA-approval is discussed, including discussion of its drug interaction potential and a review of the SPARTAN study. Updates (18:15) from ASCO GU and DOAC use in cancer (23:50) also discussed.

The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.